Drug Profile

Research programme: ultra-long acting oral HIV therapies - Gilead Sciences/Lyndra

Latest Information Update: 21 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Nov 2022 Lyndra Therapeutics receives a notice of allowance from USPTO for its ultra-long-acting oral drug delivery system in USA
17 Oct 2022 Lyndra’s in-licenses patents that broadly covers the transformative LYNX™ drug delivery platform from Massachusetts Institute of Technology and Brigham & Women’s Hospital (Lyndra website, October 2022).
17 Oct 2022 Lyndra has patents pending for LYNX™ drug delivery platform worldwide (Lyndra website, October 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com